Technical Analysis for LBPH - Longboard Pharmaceuticals, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
B | 30.92 | 14.39% | 3.89 |
LBPH closed up 14.39 percent on Monday, July 1, 2024, on 4.54 times normal volume. The bulls were able to push the stock to a new 52-week high. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week Closing High | Bullish | 0.00% | |
Expansion Breakout | Bullish Swing Setup | 0.00% | |
Pocket Pivot | Bullish Swing Setup | 0.00% | |
Volume Surge | Other | 0.00% | |
Wide Range Bar | Range Expansion | 0.00% | |
New 52 Week High | Strength | 0.00% | |
Parabolic Rise | Strength | 0.00% | |
Upper Bollinger Band Walk | Strength | 0.00% | |
Multiple of Ten Bullish | Other | 0.00% | |
Wide Bands | Range Expansion | 0.00% |
Alert | Time |
---|---|
Possible Pocket Pivot | about 6 hours ago |
Up 2 ATRs | about 6 hours ago |
Up 10% | about 7 hours ago |
Rose Above Previous Day's High | about 7 hours ago |
New 52 Week High | about 7 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/01/2024
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines for neurological diseases. Its products include LP352, a Phase I clinical trial product for the developmental and epileptic encephalopathies (DEEs) and refractory epilepsies; LP143, a product for amyotrophic lateral sclerosis and other neuroinflammatory disorders; and LP659, a product for multiple neuroinflammatory disorders. Longboard Pharmaceuticals, Inc. was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. The company was founded in 2020 and is based in San Diego, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Biology Neuroscience Epilepsy Psychiatry Amyotrophic Lateral Sclerosis Neurophysiology Neurology Nervous System Clinical Trial Product Neurological Diseases
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Biology Neuroscience Epilepsy Psychiatry Amyotrophic Lateral Sclerosis Neurophysiology Neurology Nervous System Clinical Trial Product Neurological Diseases
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 31.8 |
52 Week Low | 3.6 |
Average Volume | 411,849 |
200-Day Moving Average | 14.93 |
50-Day Moving Average | 20.23 |
20-Day Moving Average | 20.32 |
10-Day Moving Average | 22.10 |
Average True Range | 2.05 |
RSI (14) | 83.47 |
ADX | 22.08 |
+DI | 50.60 |
-DI | 9.81 |
Chandelier Exit (Long, 3 ATRs) | 25.65 |
Chandelier Exit (Short, 3 ATRs) | 21.79 |
Upper Bollinger Bands | 26.70 |
Lower Bollinger Band | 13.94 |
Percent B (%b) | 1.33 |
BandWidth | 62.77 |
MACD Line | 1.65 |
MACD Signal Line | 0.52 |
MACD Histogram | 1.1317 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 41.48 | ||||
Resistance 3 (R3) | 40.60 | 36.20 | 39.72 | ||
Resistance 2 (R2) | 36.20 | 33.51 | 36.64 | 39.13 | |
Resistance 1 (R1) | 33.56 | 31.85 | 34.88 | 34.44 | 38.55 |
Pivot Point | 29.16 | 29.16 | 29.82 | 29.60 | 29.16 |
Support 1 (S1) | 26.52 | 26.47 | 27.84 | 27.40 | 23.29 |
Support 2 (S2) | 22.12 | 24.81 | 22.56 | 22.71 | |
Support 3 (S3) | 19.48 | 22.12 | 22.12 | ||
Support 4 (S4) | 20.36 |